Skip to main content
. Author manuscript; available in PMC: 2021 Aug 3.
Published in final edited form as: Circulation. 2019 Nov 11;140(25):2076–2088. doi: 10.1161/CIRCULATIONAHA.119.043337

Figure 1. Prevalence of elevated hs-cTnT or NT-proBNP across 2017 ACC/AHA BP guideline recommended treatment groups.

Figure 1.

Elevated BP: 120–129/<80 mm Hg; stage 1 HTN: 130–139/80–89 mm Hg; stage 2 HTN: ≥140/90 mm Hg; high-risk stage 1 HTN was defined by the presence of any of the following: PCE-estimated 10-year ASCVD risk ≥10%, diabetes mellitus, estimated GFR <60 mL/min per 1.73 m2, or age ≥65 years with systolic BP ≥130 mmHg; in the absence of all of these risk factors, individuals with stage 1 HTN were classified as low-risk; hs-cTnT (+): hs-cTnT ≥6 ng/L; NT-proBNP (+): NT-proBNP ≥100 pg/mL; any biomarker (+): hs-cTnT ≥6 ng/L and/or NT-proBNP ≥100 pg/mL.

Abbreviations: anti-HTN= antihypertensive; ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; GFR = glomerular filtration rate; hs-cTnT = high-sensitivity cardiac troponin T; HTN = hypertension; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PCE = pooled cohort equation.